Esther A. Obeng

3.1k total citations · 1 hit paper
33 papers, 1.8k citations indexed

About

Esther A. Obeng is a scholar working on Molecular Biology, Hematology and Genetics. According to data from OpenAlex, Esther A. Obeng has authored 33 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 15 papers in Hematology and 8 papers in Genetics. Recurrent topics in Esther A. Obeng's work include Acute Myeloid Leukemia Research (10 papers), RNA Research and Splicing (8 papers) and RNA modifications and cancer (7 papers). Esther A. Obeng is often cited by papers focused on Acute Myeloid Leukemia Research (10 papers), RNA Research and Splicing (8 papers) and RNA modifications and cancer (7 papers). Esther A. Obeng collaborates with scholars based in United States, China and United Kingdom. Esther A. Obeng's co-authors include Lawrence Boise, Delia Gutman, William J. Harrington, Louise Carlson, Kelvin P. Lee, Omar Abdel‐Wahab, Connor Stewart, Benjamin L. Ebert, Paul J. Schmidt and Michelle C. Chen and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Esther A. Obeng

30 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells

2006 919 citations Esther A. Obeng, Lawrence Boise et al. Blood profile →

Peers

Countries citing papers authored by Esther A. Obeng

Since Specialization

Citations

This map shows the geographic impact of Esther A. Obeng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Esther A. Obeng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Esther A. Obeng more than expected).

Fields of papers citing papers by Esther A. Obeng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Esther A. Obeng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Esther A. Obeng. The network helps show where Esther A. Obeng may publish in the future.

Co-authorship network of co-authors of Esther A. Obeng

This figure shows the co-authorship network connecting the top 25 collaborators of Esther A. Obeng. A scholar is included among the top collaborators of Esther A. Obeng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Esther A. Obeng. Esther A. Obeng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clonal Hematopoiesis in Kidney Disease 2025 ·Clinical Journal of the American Society of Nephrology ·Keiichi Sumida, Esther A. Obeng, Csaba P. Kövesdy	0
2	Pediatric Transplant and Cellular Therapy Consortium RESILIENT Conference on Pediatric Chronic Graft-versus-Host Disease Survivorship after Hematopoietic Cell Transplantation: Part III. Long-Term Impact of Chronic Graft-versus-Host Disease on Endocrinologic, Cardiovascular, and Metabolic Outcomes in Survivors of Pediatric Hematopoietic Cell Transplantation 2025 ·Transplantation and Cellular Therapy ·(unknown), Jonathan D. Fish, (unknown), Gregory M.T. Guilcher, Jonathan C. Howell, Miki Nishitani, (unknown), Esther A. Obeng, Ami J. Shah, Geoff D.E. Cuvelier, Seth J. Rotz, Kirsten M. Williams, (unknown)	0
3	Dnmt3a Mutant Hematopoietic Stem Cells Produce Hyperactive T Cells with Increased Alloimmune and Anti-Leukemic Activity 2024 ·Blood ·(unknown), (unknown), Jacquelyn Myers, (unknown), (unknown), (unknown), Jaquelyn T. Zoine, Raghuvaran Shanmugam, Stefan Schattgen, Mireya Paulina Velasquez, Heather Sheppard, Jeremy Chase Crawford, (unknown), Esther A. Obeng	1
4	RNA splicing as a therapeutic target in myelodysplastic syndromes 2024 ·Seminars in Hematology ·(unknown), Esther A. Obeng	2
5	3138 – EPIGENETIC REGULATORS TET2 AND POLYCOMB REPRESSIVE COMPLEX 2 (PRC2) COORDINATE GENE EXPRESSION IN MYELODYSPLASTIC SYNDROME (MDS) 2023 ·Experimental Hematology ·Jacquelyn Myers, Elodie Henriet, (unknown), (unknown), (unknown), (unknown), Shondra M. Pruett‐Miller, (unknown), Ilaria Iacobucci, Torsten Haferlach, Charles G. Mullighan, Esther A. Obeng	0
6	SF3B1 mutation and ATM deletion codrive leukemogenesis via centromeric R-loop dysregulation 2023 ·Journal of Clinical Investigation ·(unknown), Haifeng Shen, Bo Zhang, Aijun Liao, Lu Yang, Meiling Jin, (unknown), Prajish Iyer, Yiming Wu, Kevyn L. Hart, Catherine Gutierrez, Sara Nik, Shondra M. Pruett‐Miller, Jeremy M. Stark, Esther A. Obeng, Teresa V. Bowman, Catherine J. Wu, Ren-Jang Lin, Lili Wang	18
7	Noncoding rules of survival: epigenetic regulation of normal and malignant hematopoiesis 2023 ·Frontiers in Molecular Biosciences ·(unknown), Esther A. Obeng	5
8	Hematopoietic Stem Cells from Mice and Individuals with Sickle Cell Disease Display Premature Senescence and Loss of Function That Is Targetable By Senolytic Therapy 2023 ·Blood ·(unknown), (unknown), (unknown), Esther A. Obeng, Jacquelyn Myers, Akshay Sharma, Shannon McKinney‐Freeman	2
9	Venetoclax-Based Combination Therapy As a Bridge to Allogeneic Hematopoietic Stem Cell Transplant in Children with Relapsed/Refractory AML 2022 ·Transplantation and Cellular Therapy ·Thomas Pfeiffer, Ying Li, Seth E. Karol, Jeffrey E. Rubnitz, Rebecca Epperly, Renee Madden, Ewelina Mamcarz, Esther A. Obeng, (unknown), Akshay Sharma, Ashok Srinivasan, Ali Suliman, Aimee C. Talleur, Mireya Paulina Velasquez, Stephen Gottschalk, Brandon M. Triplett, Swati Naik	2
10	Engineering naturally occurring CD7− T cells for the immunotherapy of hematological malignancies 2022 ·Blood ·(unknown), Jaquelyn T. Zoine, Jeremy Chase Crawford, Abishek Vaidya, Stefan Schattgen, Jacquelyn Myers, Sagar L. Patil, Mahsa Khanlari, Hiroto Inaba, Jeffery M. Klco, Charles G. Mullighan, Giedre Krenciute, Peter Chockley, Swati Naik, Deanna Langfitt, Maksim Mamonkin, Esther A. Obeng, Paul G. Thomas, Stephen Gottschalk, Mireya Paulina Velasquez	43
11	Splicing factor deficits render hematopoietic stem and progenitor cells sensitive to STAT3 inhibition 2022 ·Cell Reports ·Kathryn Potts, Rosannah C. Cameron, Amina Metidji, (unknown), (unknown), (unknown), (unknown), Juan M. Barajas, Varun Gupta, Srinivas Aluri, Kith Pradhan, Jacquelyn Myers, (unknown), Xiaoying Bai, Gaurav S. Choudhary, Aditi Shastri, Amit Verma, Esther A. Obeng, Teresa V. Bowman	4
12	Murine foetal liver supports limited detectable expansion of life-long haematopoietic progenitors 2022 ·Nature Cell Biology ·Miguel Ganuza, Trent Hall, Jacquelyn Myers, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), David Finkelstein, Guolian Kang, Esther A. Obeng, Shannon McKinney‐Freeman	43
13	Nonsense-Mediated RNA Decay Is a Unique Vulnerability of Cancer Cells Harboring SF3B1 or U2AF1 Mutations 2021 ·Cancer Research ·(unknown), Shan Li, Sridhar Nonavinkere Srivatsan, (unknown), Yuhao Chen, (unknown), Ying Li, Zheng Yang, Brian A. Wadugu, (unknown), Shondra M. Pruett‐Miller, Esther A. Obeng, Daniel C. Link, Dalin He, Fei Xiao, Xiaowei Wang, Julie M. Bailis, Matthew J. Walter, Zhongsheng You	37
14	Therapeutic approaches targeting splicing factor mutations in myelodysplastic syndromes and acute myeloid leukemia 2021 ·Current Opinion in Hematology ·(unknown), Juan M. Barajas, Esther A. Obeng	6
15	Impaired human hematopoiesis due to a cryptic intronic GATA1 splicing mutation 2019 ·The Journal of Experimental Medicine ·Nour J. Abdulhay, Claudia Fiorini, Jeffrey M. Verboon, Leif S. Ludwig, Jacob C. Ulirsch, Barbara Zieger, Caleb A. Lareau, Xiaoli Mi, Anindita Roy, Esther A. Obeng, Miriam Erlacher, Namrata Gupta, Stacey Gabriel, Benjamin L. Ebert, Charlotte M. Niemeyer, Rami Khoriaty, Philip Ancliff, Hanna T. Gazda, Marcin W. Włodarski, Vijay G. Sankaran	23
16	Altered RNA Processing in Cancer Pathogenesis and Therapy 2019 ·Cancer Discovery ·Esther A. Obeng, Connor Stewart, Omar Abdel‐Wahab	93
17	Phosphorylation of nucleopolyhedrovirus 39K is essential for the regulation of viral gene transcription in silkworm cells 2019 ·Acta Virologica ·Hui‐chao Yan, (unknown), Ming Wei, Esther A. Obeng, Shengjie Xue, (unknown), Yanping Quan, Yu Wang	4
18	Physiologic Expression of Sf3b1 K700E Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation 2016 ·Cancer Cell ·Esther A. Obeng, (unknown), Michael Seiler, Michelle C. Chen, Dean R. Campagna, Paul J. Schmidt, Rebekka K. Schneider, Allegra M. Lord, Lili Wang, Rutendo Gambe, Marie McConkey, Abdullah Mahmood Ali, Azra Raza, Lihua Yu, Silvia Buonamici, Peter G. Smith, Ann Mullally, Catherine J. Wu, Mark D. Fleming, Benjamin L. Ebert	263
19	Pediatric Heparin-Induced Thrombocytopenia: Prevalence, Thrombotic Risk, and Application of the 4Ts Scoring System 2014 ·The Journal of Pediatrics ·Esther A. Obeng, (unknown), Thomas Moniz, Alana Arnold, Ellis J. Neufeld, Cameron C. Trenor	37
20	Caspase-12 and Caspase-4 Are Not Required for Caspase-dependent Endoplasmic Reticulum Stress-induced Apoptosis 2005 ·Journal of Biological Chemistry ·Esther A. Obeng, Lawrence Boise	148

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact